COSMO Pharmaceuticals N.V. (CH:COPN)
:COPN
COPN Stock Chart & Stats
CHF80.20
-CHF3.50(-5.38%)
At close: 4:00 PM EST
CHF80.20
-CHF3.50(-5.38%)
Day’s Range― - ―
52-Week RangeCHF41.60 - CHF129.40
Previous CloseN/A
Volume25.75K
Average Volume (3M)19.52K
Market Cap
CHF1.35B
Enterprise ValueCHF1.36B
Total Cash (Recent Filing)CHF122.66M
Total Debt (Recent Filing)CHF4.26M
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Jul 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.82%
Share Statistics
EPS (TTM)-0.09
Shares Outstanding17,543,522
10 Day Avg. Volume18,700
30 Day Avg. Volume19,520
Financial Highlights & Ratios
PEG Ratio4.83
Price to Book (P/B)3.74
Price to Sales (P/S)17.21
P/FCF Ratio-113.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF135.00Price Target Upside68.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.08
Revenue Forecast (FY)CHF109.67M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetCosmo's very low debt ratios and substantial equity provide durable financial optionality. This strength supports funding R&D, absorbing product-cycle volatility, and pursuing partnerships or tuck-in deals without immediate reliance on markets, improving resilience across economic cycles.
Specialized Gastroenterology FocusA focused product set for gastroenterologists and endoscopy centers builds domain expertise and client relationships. Structural demand for GI care and procedural devices creates recurring addressable demand, giving Cosmo durable competitive positioning in a niche medical market.
Diversified Revenue MechanicsA mix of direct product sales and licensing income (upfronts, milestones, royalties) creates multi-year revenue streams and de-risks reliance on a single product launch. This model can smooth cash flow over time and align partner incentives for commercialization.
Bears Say
Profitability VolatilityA swing from very strong margins in 2024 to negative EBIT and net margins in 2025 signals unreliable earnings power. Persistent profitability volatility undermines long-term planning, makes sustained R&D and commercial investments riskier, and complicates partner negotiations.
Deteriorating Cash GenerationA move to negative operating and free cash flow reduces the firm's ability to self-fund operations and investment. Even with ample equity, negative cash generation can force project delays, reliance on external financing or partner deals, and restrict strategic flexibility over coming quarters.
Inconsistent Historical PerformanceThe firm’s track record of intermittent losses and sharp year-to-year swings points to execution and demand risk. Inconsistent performance limits scale economies and heightens the chance that future product cycles will produce uneven returns, complicating long-term forecasting.
COSMO Pharmaceuticals N.V. News
COPN FAQ
What was COSMO Pharmaceuticals N.V.’s price range in the past 12 months?
COSMO Pharmaceuticals N.V. lowest stock price was CHF41.60 and its highest was CHF129.40 in the past 12 months.
What is COSMO Pharmaceuticals N.V.’s market cap?
COSMO Pharmaceuticals N.V.’s market cap is CHF1.35B.
When is COSMO Pharmaceuticals N.V.’s upcoming earnings report date?
COSMO Pharmaceuticals N.V.’s upcoming earnings report date is Jul 29, 2026 which is in 122 days.
How were COSMO Pharmaceuticals N.V.’s earnings last quarter?
COSMO Pharmaceuticals N.V. released its earnings results on Mar 09, 2026. The company reported -CHF0.092 earnings per share for the quarter, missing the consensus estimate of CHF0.184 by -CHF0.277.
Is COSMO Pharmaceuticals N.V. overvalued?
According to Wall Street analysts COSMO Pharmaceuticals N.V.’s price is currently Undervalued.
Does COSMO Pharmaceuticals N.V. pay dividends?
COSMO Pharmaceuticals N.V. pays a Annually dividend of CHF1.918 which represents an annual dividend yield of 1.82%. See more information on COSMO Pharmaceuticals N.V. dividends here
What is COSMO Pharmaceuticals N.V.’s EPS estimate?
COSMO Pharmaceuticals N.V.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does COSMO Pharmaceuticals N.V. have?
COSMO Pharmaceuticals N.V. has 17,543,522 shares outstanding.
What happened to COSMO Pharmaceuticals N.V.’s price movement after its last earnings report?
COSMO Pharmaceuticals N.V. reported an EPS of -CHF0.092 in its last earnings report, missing expectations of CHF0.184. Following the earnings report the stock price went down -10.521%.
Which hedge fund is a major shareholder of COSMO Pharmaceuticals N.V.?
Currently, no hedge funds are holding shares in CH:COPN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris. In addition, it offers Clascoterone, an androgen receptor inhibitor that targets in the scalp and androgenetic alopecia; Rifamycin for irritable bowel syndrome with diarrhoea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for procedural sedation; CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a single use enema formulation. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.
COPN Stock 12 Month Forecast
Average Price Target
CHF135.00
▲(68.33% Upside)
Technical Analysis
Options Prices
Currently, No data available
---